Specify Company / Ticker to Get the Summary
Implantica AG
IMP-A-SDBImplantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a remote controlled artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for the treatment of aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Address: Aeulestrasse 45, Vaduz, Liechtenstein, 9490
Analytics
WallStreet Target Price
591.88 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IMP-A-SDB
Dividend Analytics IMP-A-SDB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMP-A-SDB
Stock Valuation IMP-A-SDB
Financials IMP-A-SDB
Results | 2019 | Dynamics |